Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic and Statistical Manual - Fourth Edition (DSM-IV) diagnosis of schizoaffective disorder~* A total Positive and Negative Symptoms of Schizophrenia (PANSS) score of \>= 60~* A score of \>= 16 on Young Mania Rating Scale (YMRS) or a score of \>= 16 on the Hamilton Depression Rating Scale (HAM-D 21)~Exclusion Criteria:~* A primary active mental illness diagnosis other than schizoaffective disorder~* Patients with first episode psychosis~* Active substance dependence within previous 6 months~* Treatment with clozapine within 6 months of randomization~* A history of treatment resistance, defined by failure to respond to 2 adequate trials of antipsychotic medication~* Pregnancy, breast-feeding, or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
- 003 (Type: EXPERIMENTAL): Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
- 002 (Type: PLACEBO_COMPARATOR): Placebo for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).